bpc-157 & tb-500 / Capsules BPC-157/TB500 Recovery & Repair Stack

Expert content reviewers: This information was developed with the help of a range of health professionals and people affected by stomach cancer: Prof David I Watson, Matthew Flinders Distinguished Professor of Surgery, Flinders University, and Senior Consultant Surgeon, Oesophago-Gastric Surgery Unit, Flinders Medical Centre, SA Prof Bryan Burmeister, Senior Radiation Oncologist, GenesisCare Fraser Coast and Hervey Bay Hospital, QLD Dr Natalie Collier, Radiation Oncologist, Wollongong Hospital, NSW A/Prof Melissa Eastgate, A/Executive Director, Cancer Care Services, Royal Brisbane and Womens Hospital, QLD Brett Hall, Consumer Natalie Lalor, 13 11 20 Consultant, Cancer Council Victoria Chris Menzies, Upper GI Cancer Nurse Consultant, Flinders Medical Centre and Southern Adelaide Local Health Network, SA Stefanie Simnadis, Clinical Dietitian, St John of God Subiaco Hospital, WA Prof Rajvinder Singh, Professor of Medicine, University of Adelaide, and Director, Gastroenterology Department and Head of Endoscopy, Lyell McEwin Hospital, SA

(2024, March 5)

A 2023 pharmaceutical review pointed out that BPC-157 increases expression of VEGFR2, a key receptor for vascular growth, in animal models

What is globally accepted for peptides in solution is that they are generally stable for 3 or more weeks at +4C and for 3-4 months at -20C